Plasma radiometabolite correction in dynamic PET studies: Insights on the available modeling approaches

Full kinetic modeling of dynamic PET images requires the measurement of radioligand concentrations in the arterial plasma. The unchanged parent radioligand must, however, be separated from its radiometabolites by chromatographic methods. Thus, only few samples can usually be analyzed and the resulting measurements are often noisy. Therefore, the measurements must be fitted with a mathematical model. This work presents a comprehensive analysis of the different models proposed in the literature to describe the plasma parent fraction (PPf) and of the alternative approaches for radiometabolite correction. Finally, we used a dataset of [11C]PBR28 brain PET data as a case study to guide the reader through the PPf model selection process.

[1]  M Schwaiger,et al.  Effect of carbon-11-acetate recirculation on estimates of myocardial oxygen consumption by PET. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  Tuula Tolvanen,et al.  Evaluation of 68Ga-labeled tracers for PET imaging of myocardial perfusion in pigs. , 2012, Nuclear medicine and biology.

[3]  Roger N Gunn,et al.  Quantification of the Specific Translocator Protein Signal of 18F-PBR111 in Healthy Humans: A Genetic Polymorphism Effect on In Vivo Binding , 2013, The Journal of Nuclear Medicine.

[4]  Marie-Claude Asselin,et al.  Quantification of PET Studies with the Very High-Affinity Dopamine D2/D3 Receptor Ligand [11C]FLB 457: Re-Evaluation of the Validity of using a Cerebellar Reference Region , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  R. Frackowiak,et al.  Measurement of Cerebral Monoamine Oxidase B Activity Using L-[11C]Deprenyl and Dynamic Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  Sadahiko Nishizawa,et al.  Simple analytic method of 11C-flumazenil metabolite in blood. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  John D. Beaver,et al.  Mathematical modelling of [11C]-(+)-PHNO human competition studies , 2013, NeuroImage.

[8]  W. L. Chiou,et al.  The Phenomenon and Rationale of Marked Dependence of Drug Concentration on Blood Sampling Site , 1989, Clinical pharmacokinetics.

[9]  S. Sanabria-Bohórquez,et al.  [11C]Flumazenil metabolite measurement in plasma is not necessary for accurate brain benzodiazepine receptor quantification , 2000, European Journal of Nuclear Medicine.

[10]  Roger N. Gunn,et al.  Tracer Kinetic Modeling of the 5-HT1AReceptor Ligand [carbonyl-11C]WAY-100635 for PET , 1998, NeuroImage.

[11]  Jeih-San Liow,et al.  PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Marie Davidian,et al.  Nonlinear models for repeated measurement data: An overview and update , 2003 .

[13]  Vesa Oikonen Effect of tracer metabolism during sample preparation , 2014 .

[14]  Claudio Cobelli,et al.  Tracer Kinetics In Biomedical Research , 2000 .

[15]  Alessandra Bertoldo,et al.  A non-linear mixed effect modelling approach for metabolite correction of the arterial input function in PET studies , 2013, NeuroImage.

[16]  Alessandra Bertoldo,et al.  Improved Models for Plasma Radiometabolite Correction and their Impact on Kinetic Quantification in PET Studies , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  Cyrill Burger,et al.  Tracer kinetic modelling of receptor data with mathematical metabolite correction , 1996, European Journal of Nuclear Medicine.

[18]  D. Mankoff,et al.  Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  Ryuji Nakao,et al.  Quantitative Analysis for Estimating Binding Potential of the Peripheral Benzodiazepine Receptor with [11C]DAA1106 , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  Fumitoshi Kodaka,et al.  Quantification of Dopamine Transporter in Human Brain Using PET with 18F-FE-PE2I , 2012, The Journal of Nuclear Medicine.

[21]  Mark Lubberink,et al.  Comparison of Plasma Input and Reference Tissue Models for Analysing [11C]flumazenil Studies , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  W C Eckelman,et al.  Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  Chie Seki,et al.  Effect of tracer metabolism on PET measurement of [11C]pyrilamine binding to histamine H1 receptors , 1999, Annals of nuclear medicine.

[24]  Christopher C Rowe,et al.  Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET. , 2005, Nuclear medicine and biology.

[25]  Annelaure Damont,et al.  Metabolism and Quantification of [18F]DPA-714, a New TSPO Positron Emission Tomography Radioligand , 2013, Drug Metabolism and Disposition.

[26]  Effects of Metabolite Correction for Arterial Input Function on Quantitative Receptor Images With 11C-Flumazenil in Clinical Positron Emission Tomography Studies , 2004, Journal of computer assisted tomography.

[27]  J C Mazziotta,et al.  Estimation of Local Cerebral Protein Synthesis Rates with L-[1-11C]Leucine and PET: Methods, Model, and Results in Animals and Humans , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  Alan C. Evans,et al.  Human Striatal l-DOPA Decarboxylase Activity Estimated in vivo Using 6-[18F]fluoro-DOPA and Positron Emission Tomography: Error Analysis and Application to Normal Subjects , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  Mark Lubberink,et al.  Evaluation of Tracer Kinetic Models for Quantification of P-Glycoprotein Function using (R)-[11C]Verapamil and PET , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[30]  M. Pomper,et al.  Initial Evaluation of 11C-DPA-713, a Novel TSPO PET Ligand, in Humans , 2009, Journal of Nuclear Medicine.

[31]  Gaia Rizzo,et al.  Imaging of monoamine oxidase-A in the human brain with [11C]befloxatone: quantification strategies and correlation with mRNA transcription maps , 2014, Nuclear medicine communications.

[32]  Karl Zilles,et al.  Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET: an equilibrium approach , 2005, NeuroImage.

[33]  D. Visvikis,et al.  Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  Tadashi Nariai,et al.  Metabolite analysis of [11C]flumazenil in human plasma: Assessment as the standardized value for quantitative PET studies , 1998, Annals of nuclear medicine.

[35]  Alessandra Bertoldo,et al.  Kinetic Modeling without Accounting for the Vascular Component Impairs the Quantification of [11C]PBR28 Brain PET Data , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  Victor W Pike,et al.  PET radiotracers: crossing the blood-brain barrier and surviving metabolism. , 2009, Trends in pharmacological sciences.

[37]  Ronald Boellaard,et al.  Development of a Tracer Kinetic Plasma Input Model for (R)-[11C]PK11195 Brain Studies , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[38]  A. Gjedde,et al.  Pharmacokinetics of Plasma 6-[18F]Fluoro-l-3,4-Dihydroxyphenylalanine ([18F]FDOPA) in Humans , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[39]  Ramin V. Parsey,et al.  Optimal Metabolite Curve Fitting for Kinetic Modeling of 11C-WAY-100635 , 2007, Journal of Nuclear Medicine.

[40]  H. Akaike A new look at the statistical model identification , 1974 .

[41]  Christer Halldin,et al.  Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects , 2012, EJNMMI Research.

[42]  W C Eckelman,et al.  Kinetic Analysis of the 5-HT2A Ligand [11C]MDL 100,907 , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[43]  Masahiro Fujita,et al.  In vitro and in vivo evaluation of 11C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors , 2014, NeuroImage.

[44]  Kewei Chen,et al.  Image-Derived Input Function for Brain PET Studies: Many Challenges and Few Opportunities , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[45]  Tuula Tolvanen,et al.  Whole-body distribution and metabolism of [N-methyl-11C](R)-1-(2-chlorophenyl)-N-(1-methylpropyl)-3-isoquinolinecarboxamide in humans; an imaging agent for in vivo assessment of peripheral benzodiazepine receptor activity with positron emission tomography , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[46]  Nelleke Tolboom,et al.  Evaluation of Tracer Kinetic Models for Analysis of [18F]FDDNP Studies , 2009, Molecular Imaging and Biology.

[47]  G. Schwarz Estimating the Dimension of a Model , 1978 .

[48]  Vincent J Cunningham,et al.  Validation of a Tracer Kinetic Model for the Quantification of 5-HT2A Receptors in Human Brain with [11C]MDL 100,907 , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[49]  Paul Edison,et al.  Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility , 2009, NeuroImage.

[50]  Karl J. Friston,et al.  Bayesian model selection for group studies , 2009, NeuroImage.

[51]  Yuichi Kimura,et al.  Quantitative analysis of adenosine A1 receptors in human brain using positron emission tomography and [1-methyl-11C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine. , 2004, Nuclear medicine and biology.

[52]  Oliver Gaemperli,et al.  Detection and Quantification of Large-Vessel Inflammation with 11C-(R)-PK11195 PET/CT , 2011, The Journal of Nuclear Medicine.

[53]  Talakad G. Lohith,et al.  Evaluation in monkey of two candidate PET radioligands, [11C]RX‐1 and [18F]RX‐2, for imaging brain 5‐HT4 receptors , 2014, Synapse.

[54]  N. Simpson,et al.  PET Studies of Binding Competition between Endogenous Dopamine and the D1 Radiotracer [11C]NNC 756 , 1998, NeuroImage.

[55]  Otto Muzik,et al.  A simplified analysis of [18F]3′-deoxy-3′-fluorothymidine metabolism and retention , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[56]  Badreddine Bencherif,et al.  Quantification of brain mu-opioid receptors with [11C]carfentanil: reference-tissue methods. , 2003, Nuclear medicine and biology.

[57]  S. Gunn,et al.  Positron Emission Tomography Compartmental Models , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[58]  Christer Halldin,et al.  Measurement of Striatal and Extrastriatal Dopamine Transporter Binding with High-Resolution PET and [11C]PE2I: Quantitative Modeling and Test—Retest Reproducibility , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[59]  Alexander Hammers,et al.  Balancing bias, reliability, noise properties and the need for parametric maps in quantitative ligand PET: [11C]diprenorphine test–retest data , 2007, NeuroImage.

[60]  Peter Herscovitch,et al.  Propofol Decreases In Vivo Binding of 11C-PBR28 to Translocator Protein (18 kDa) in the Human Brain , 2013, The Journal of Nuclear Medicine.

[61]  R. V. Van Heertum,et al.  Metabolite considerations in the in vivo quantification of serotonin transporters using 11C-DASB and PET in humans. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[62]  Roger N Gunn,et al.  Determination of [11C]PBR28 Binding Potential in vivo: A First Human TSPO Blocking Study , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[63]  Richard E. Carson,et al.  Evaluation of the agonist PET radioligand [11C]GR103545 to image kappa opioid receptor in humans: Kinetic model selection, test–retest reproducibility and receptor occupancy by the antagonist PF-04455242 , 2014, NeuroImage.

[64]  D J Brooks,et al.  Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[65]  Valerie Treyer,et al.  Stimulation-Induced Increases of Astrocytic Oxidative Metabolism in Rats and Humans Investigated with 1-11C-Acetate , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[66]  Lula Rosso,et al.  Evaluation of limited blood sampling population input approaches for kinetic quantification of [18F]fluorothymidine PET data , 2012, EJNMMI Research.

[67]  Susan P. Hume,et al.  Quantification of [11C]GB67 binding to cardiac α1-adrenoceptors with positron emission tomography: validation in pigs , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[68]  Eveliina Arponen,et al.  11C-ORM-13070, a novel PET ligand for brain α2C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[69]  R. Carson,et al.  The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [11C]PBR28 PET study , 2013, Brain, Behavior, and Immunity.

[70]  Talakad G. Lohith,et al.  Brain and Whole-Body Imaging of Nociceptin/Orphanin FQ Peptide Receptor in Humans Using the PET Ligand 11C-NOP-1A , 2012, The Journal of Nuclear Medicine.

[71]  J C Mazziotta,et al.  Modelling approach for separating blood time-activity curves in positron emission tomographic studies. , 1991, Physics in medicine and biology.

[72]  Klaus Wienhard,et al.  Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.